Table 1. Open in new tab Incidence Rates...

	Diabetic Individuals	Nondiabetics Individuals	Difference
Total study population
Enrollees in group	61 142	7 681 336	7.96	(7.90–8.02)	359 373	80 266 547	4.48	(4.46–4.49)	1.78	(1.76–1.79)
Sex
Females	35 071	3 826 046	9.17	(9.07–9.26)	224 735	43 431 997	5.17	(5.15–5.20)	1.77	(1.75–1.79)
Males	26 071	3 855 290	6.76	(6.68–6.85)	134 638	36 834 550	3.66	(3.64–3.68)	1.85	(1.83–1.87)
Age group
18–49 years	12 441	2 464 386	5.05	(4.96–5.14)	169 277	51 819 510	3.27	(3.25–3.28)	1.55	(1.52–1.57)
50–59 years	22 284	2 821 550	7.90	(7.79–8.00)	104 908	17 041 888	6.16	(6.12–6.19)	1.28	(1.26–1.30)
60–64 years	9619	993 001	9.69	(9.49–9.88)	31 838	4 396 777	7.24	(7.16–7.32)	1.34	(1.31–1.37)
≥65 years	16 798	1 402 399	11.98	(11.80–12.16)	53 350	7 008 371	7.61	(7.55–7.68)	1.57	(1.55–1.60)
Immune competent
Enrollees in group	56 261	7 309 166	7.70	(7.63–7.76)	335 809	78 133 941	4.30	(4.28–4.31)	1.79	(1.78–1.81)
Sex
Females	32 308	3 632 648	8.89	(8.80–8.99)	209 521	42 154 331	4.97	(4.95–4.99)	1.79	(1.77–1.81)
Males	23 953	3 676 518	6.52	(6.43–6.60)	126 288	35 979 610	3.51	(3.49–3.53)	1.86	(1.83–1.88)
Age group
18–49 years	11 670	2 394 113	4.87	(4.79–4.96)	162 206	50 979 189	3.18	(3.17–3.20)	1.53	(1.50–1.56)
50–59 years	20 682	2 694 694	7.68	(7.57–7.78)	97 670	16 397 987	5.96	(5.92–5.99)	1.29	(1.27–1.31)
60–64 years	8803	933 587	9.43	(9.23–9.63)	28 881	4 169 442	6.93	(6.85–7.01)	1.36	(1.33–1.39)
≥65 years	15 106	1 286 772	11.74	(11.55–11.93)	47 052	6 587 323	7.14	(7.08–7.21)	1.64	(1.61–1.67)
Immune compromised
Enrollees in group	4881	372 169	13.12	(12.75–13.49)	23 564	2 132 606	11.05	(10.91–11.19)	1.19	(1.15–1.22)
Sex
Females	2763	193 398	14.29	(13.76–14.83)	15 214	1 277 666	11.91	(11.72–12.10)	1.20	(1.15–1.25)
Males	2118	178 772	11.85	(11.35–12.36)	8350	854 940	9.77	(9.56–9.98)	1.21	(1.16–1.27)
Age group
18–49 years	771	70 273	10.97	(10.21–11.77)	7071	840 321	8.41	(8.22–8.61)	1.30	(1.21–1.40)
50–59 years	1602	126 856	12.63	(12.02–13.26)	7238	643 902	11.24	(10.98–11.50)	1.12	(1.06–1.19)
60–64 years	816	59 414	13.73	(12.81–14.71)	2957	227 335	13.01	(12.54–13.49)	1.06	(0.98–1.14)
≥65 years	1692	115 627	14.63	(13.94–15.35)	6298	421 048	14.96	(14.59–15.33)	0.98	(0.93–1.03)

Diabetic Individuals

Nondiabetics Individuals

Difference

Herpes Zoster Cases

Person- Years (PY)

Cases/ 1000 PY

95% Confidence Interval [CI]*

Herpes Zoster Cases

Person- Years (PY)

Cases/ 1000 PY

95% CI*

Incidence Rate Ratio

95% CI**

Total study population

Enrollees in group

61 142

7 681 336

7.96

(7.90–8.02)

359 373

80 266 547

4.48

(4.46–4.49)

1.78

(1.76–1.79)

Sex

Females

35 071

3 826 046

9.17

(9.07–9.26)

224 735

43 431 997

5.17

(5.15–5.20)

1.77

(1.75–1.79)

Males

26 071

3 855 290

6.76

(6.68–6.85)

134 638

36 834 550

3.66

(3.64–3.68)

1.85

(1.83–1.87)

Age group

18–49 years

12 441

2 464 386

5.05

(4.96–5.14)

169 277

51 819 510

3.27

(3.25–3.28)

1.55

(1.52–1.57)

50–59 years

22 284

2 821 550

7.90

(7.79–8.00)

104 908

17 041 888

6.16

(6.12–6.19)

1.28

(1.26–1.30)

60–64 years

9619

993 001

9.69

(9.49–9.88)

31 838

4 396 777

7.24

(7.16–7.32)

1.34

(1.31–1.37)

≥65 years

16 798

1 402 399

11.98

(11.80–12.16)

53 350

7 008 371

7.61

(7.55–7.68)

1.57

(1.55–1.60)

Immune competent

Enrollees in group

56 261

7 309 166

7.70

(7.63–7.76)

335 809

78 133 941

4.30

(4.28–4.31)

1.79

(1.78–1.81)

Sex

Females

32 308

3 632 648

8.89

(8.80–8.99)

209 521

42 154 331

4.97

(4.95–4.99)

1.79

(1.77–1.81)

Males

23 953

3 676 518

6.52

(6.43–6.60)

126 288

35 979 610

3.51

(3.49–3.53)

1.86

(1.83–1.88)

Age group

18–49 years

11 670

2 394 113

4.87

(4.79–4.96)

162 206

50 979 189

3.18

(3.17–3.20)

1.53

(1.50–1.56)

50–59 years

20 682

2 694 694

7.68

(7.57–7.78)

97 670

16 397 987

5.96

(5.92–5.99)

1.29

(1.27–1.31)

60–64 years

8803

933 587

9.43

(9.23–9.63)

28 881

4 169 442

6.93

(6.85–7.01)

1.36

(1.33–1.39)

≥65 years

15 106

1 286 772

11.74

(11.55–11.93)

47 052

6 587 323

7.14

(7.08–7.21)

1.64

(1.61–1.67)

Immune compromised

Enrollees in group

4881

372 169

13.12

(12.75–13.49)

23 564

2 132 606

11.05

(10.91–11.19)

1.19

(1.15–1.22)

Sex

Females

2763

193 398

14.29

(13.76–14.83)

15 214

1 277 666

11.91

(11.72–12.10)

1.20

(1.15–1.25)

Males

2118

178 772

11.85

(11.35–12.36)

8350

854 940

9.77

(9.56–9.98)

1.21

(1.16–1.27)

Age group

18–49 years

771

70 273

10.97

(10.21–11.77)

7071

840 321

8.41

(8.22–8.61)

1.30

(1.21–1.40)

50–59 years

1602

126 856

12.63

(12.02–13.26)

7238

643 902

11.24

(10.98–11.50)

1.12

(1.06–1.19)

60–64 years

816

59 414

13.73

(12.81–14.71)

2957

227 335

13.01

(12.54–13.49)

1.06

(0.98–1.14)

≥65 years

1692

115 627

14.63

(13.94–15.35)

6298

421 048

14.96

(14.59–15.33)

0.98

(0.93–1.03)

	Diabetic Individuals	Nondiabetics Individuals	Difference
Total study population
Enrollees in group	61 142	7 681 336	7.96	(7.90–8.02)	359 373	80 266 547	4.48	(4.46–4.49)	1.78	(1.76–1.79)
Sex
Females	35 071	3 826 046	9.17	(9.07–9.26)	224 735	43 431 997	5.17	(5.15–5.20)	1.77	(1.75–1.79)
Males	26 071	3 855 290	6.76	(6.68–6.85)	134 638	36 834 550	3.66	(3.64–3.68)	1.85	(1.83–1.87)
Age group
18–49 years	12 441	2 464 386	5.05	(4.96–5.14)	169 277	51 819 510	3.27	(3.25–3.28)	1.55	(1.52–1.57)
50–59 years	22 284	2 821 550	7.90	(7.79–8.00)	104 908	17 041 888	6.16	(6.12–6.19)	1.28	(1.26–1.30)
60–64 years	9619	993 001	9.69	(9.49–9.88)	31 838	4 396 777	7.24	(7.16–7.32)	1.34	(1.31–1.37)
≥65 years	16 798	1 402 399	11.98	(11.80–12.16)	53 350	7 008 371	7.61	(7.55–7.68)	1.57	(1.55–1.60)
Immune competent
Enrollees in group	56 261	7 309 166	7.70	(7.63–7.76)	335 809	78 133 941	4.30	(4.28–4.31)	1.79	(1.78–1.81)
Sex
Females	32 308	3 632 648	8.89	(8.80–8.99)	209 521	42 154 331	4.97	(4.95–4.99)	1.79	(1.77–1.81)
Males	23 953	3 676 518	6.52	(6.43–6.60)	126 288	35 979 610	3.51	(3.49–3.53)	1.86	(1.83–1.88)
Age group
18–49 years	11 670	2 394 113	4.87	(4.79–4.96)	162 206	50 979 189	3.18	(3.17–3.20)	1.53	(1.50–1.56)
50–59 years	20 682	2 694 694	7.68	(7.57–7.78)	97 670	16 397 987	5.96	(5.92–5.99)	1.29	(1.27–1.31)
60–64 years	8803	933 587	9.43	(9.23–9.63)	28 881	4 169 442	6.93	(6.85–7.01)	1.36	(1.33–1.39)
≥65 years	15 106	1 286 772	11.74	(11.55–11.93)	47 052	6 587 323	7.14	(7.08–7.21)	1.64	(1.61–1.67)
Immune compromised
Enrollees in group	4881	372 169	13.12	(12.75–13.49)	23 564	2 132 606	11.05	(10.91–11.19)	1.19	(1.15–1.22)
Sex
Females	2763	193 398	14.29	(13.76–14.83)	15 214	1 277 666	11.91	(11.72–12.10)	1.20	(1.15–1.25)
Males	2118	178 772	11.85	(11.35–12.36)	8350	854 940	9.77	(9.56–9.98)	1.21	(1.16–1.27)
Age group
18–49 years	771	70 273	10.97	(10.21–11.77)	7071	840 321	8.41	(8.22–8.61)	1.30	(1.21–1.40)
50–59 years	1602	126 856	12.63	(12.02–13.26)	7238	643 902	11.24	(10.98–11.50)	1.12	(1.06–1.19)
60–64 years	816	59 414	13.73	(12.81–14.71)	2957	227 335	13.01	(12.54–13.49)	1.06	(0.98–1.14)
≥65 years	1692	115 627	14.63	(13.94–15.35)	6298	421 048	14.96	(14.59–15.33)	0.98	(0.93–1.03)

Diabetic Individuals

Nondiabetics Individuals

Difference

Herpes Zoster Cases

Person- Years (PY)

Cases/ 1000 PY

95% Confidence Interval [CI]*

Herpes Zoster Cases

Person- Years (PY)

Cases/ 1000 PY

95% CI*

Incidence Rate Ratio

95% CI**

Total study population

Enrollees in group

61 142

7 681 336

7.96

(7.90–8.02)

359 373

80 266 547

4.48

(4.46–4.49)

1.78

(1.76–1.79)

Sex

Females

35 071

3 826 046

9.17

(9.07–9.26)

224 735

43 431 997

5.17

(5.15–5.20)

1.77

(1.75–1.79)

Males

26 071

3 855 290

6.76

(6.68–6.85)

134 638

36 834 550

3.66

(3.64–3.68)

1.85

(1.83–1.87)

Age group

18–49 years

12 441

2 464 386

5.05

(4.96–5.14)

169 277

51 819 510

3.27

(3.25–3.28)

1.55

(1.52–1.57)

50–59 years

22 284

2 821 550

7.90

(7.79–8.00)

104 908

17 041 888

6.16

(6.12–6.19)

1.28

(1.26–1.30)

60–64 years

9619

993 001

9.69

(9.49–9.88)

31 838

4 396 777

7.24

(7.16–7.32)

1.34

(1.31–1.37)

≥65 years

16 798

1 402 399

11.98

(11.80–12.16)

53 350

7 008 371

7.61

(7.55–7.68)

1.57

(1.55–1.60)

Immune competent

Enrollees in group

56 261

7 309 166

7.70

(7.63–7.76)

335 809

78 133 941

4.30

(4.28–4.31)

1.79

(1.78–1.81)

Sex

Females

32 308

3 632 648

8.89

(8.80–8.99)

209 521

42 154 331

4.97

(4.95–4.99)

1.79

(1.77–1.81)

Males

23 953

3 676 518

6.52

(6.43–6.60)

126 288

35 979 610

3.51

(3.49–3.53)

1.86

(1.83–1.88)

Age group

18–49 years

11 670

2 394 113

4.87

(4.79–4.96)

162 206

50 979 189

3.18

(3.17–3.20)

1.53

(1.50–1.56)

50–59 years

20 682

2 694 694

7.68

(7.57–7.78)

97 670

16 397 987

5.96

(5.92–5.99)

1.29

(1.27–1.31)

60–64 years

8803

933 587

9.43

(9.23–9.63)

28 881

4 169 442

6.93

(6.85–7.01)

1.36

(1.33–1.39)

≥65 years

15 106

1 286 772

11.74

(11.55–11.93)

47 052

6 587 323

7.14

(7.08–7.21)

1.64

(1.61–1.67)

Immune compromised

Enrollees in group

4881

372 169

13.12

(12.75–13.49)

23 564

2 132 606

11.05

(10.91–11.19)

1.19

(1.15–1.22)

Sex

Females

2763

193 398

14.29

(13.76–14.83)

15 214

1 277 666

11.91

(11.72–12.10)

1.20

(1.15–1.25)

Males

2118

178 772

11.85

(11.35–12.36)

8350

854 940

9.77

(9.56–9.98)

1.21

(1.16–1.27)

Age group

18–49 years

771

70 273

10.97

(10.21–11.77)

7071

840 321

8.41

(8.22–8.61)

1.30

(1.21–1.40)

50–59 years

1602

126 856

12.63

(12.02–13.26)

7238

643 902

11.24

(10.98–11.50)

1.12

(1.06–1.19)

60–64 years

816

59 414

13.73

(12.81–14.71)

2957

227 335

13.01

(12.54–13.49)

1.06

(0.98–1.14)

≥65 years

1692

115 627

14.63

(13.94–15.35)

6298

421 048

14.96

(14.59–15.33)

0.98

(0.93–1.03)

Table 1.

Open in new tab

Incidence Rates of Herpes Zoster by Diabetes and Concomitant Immune-Compromised Status, 2005–2009

	Diabetic Individuals				Nondiabetics Individuals				Difference
	Herpes Zoster Cases	Person- Years (PY)	Cases/ 1000 PY	95% Confidence Interval [CI]*	Herpes Zoster Cases	Person- Years (PY)	Cases/ 1000 PY	95% CI*	Incidence Rate Ratio	95% CI**
Total study population
Enrollees in group	61 142	7 681 336	7.96	(7.90–8.02)	359 373	80 266 547	4.48	(4.46–4.49)	1.78	(1.76–1.79)
Sex
Females	35 071	3 826 046	9.17	(9.07–9.26)	224 735	43 431 997	5.17	(5.15–5.20)	1.77	(1.75–1.79)
Males	26 071	3 855 290	6.76	(6.68–6.85)	134 638	36 834 550	3.66	(3.64–3.68)	1.85	(1.83–1.87)
Age group
18–49 years	12 441	2 464 386	5.05	(4.96–5.14)	169 277	51 819 510	3.27	(3.25–3.28)	1.55	(1.52–1.57)
50–59 years	22 284	2 821 550	7.90	(7.79–8.00)	104 908	17 041 888	6.16	(6.12–6.19)	1.28	(1.26–1.30)
60–64 years	9619	993 001	9.69	(9.49–9.88)	31 838	4 396 777	7.24	(7.16–7.32)	1.34	(1.31–1.37)
≥65 years	16 798	1 402 399	11.98	(11.80–12.16)	53 350	7 008 371	7.61	(7.55–7.68)	1.57	(1.55–1.60)
Immune competent
Enrollees in group	56 261	7 309 166	7.70	(7.63–7.76)	335 809	78 133 941	4.30	(4.28–4.31)	1.79	(1.78–1.81)
Sex
Females	32 308	3 632 648	8.89	(8.80–8.99)	209 521	42 154 331	4.97	(4.95–4.99)	1.79	(1.77–1.81)
Males	23 953	3 676 518	6.52	(6.43–6.60)	126 288	35 979 610	3.51	(3.49–3.53)	1.86	(1.83–1.88)
Age group
18–49 years	11 670	2 394 113	4.87	(4.79–4.96)	162 206	50 979 189	3.18	(3.17–3.20)	1.53	(1.50–1.56)
50–59 years	20 682	2 694 694	7.68	(7.57–7.78)	97 670	16 397 987	5.96	(5.92–5.99)	1.29	(1.27–1.31)
60–64 years	8803	933 587	9.43	(9.23–9.63)	28 881	4 169 442	6.93	(6.85–7.01)	1.36	(1.33–1.39)
≥65 years	15 106	1 286 772	11.74	(11.55–11.93)	47 052	6 587 323	7.14	(7.08–7.21)	1.64	(1.61–1.67)
Immune compromised
Enrollees in group	4881	372 169	13.12	(12.75–13.49)	23 564	2 132 606	11.05	(10.91–11.19)	1.19	(1.15–1.22)
Sex
Females	2763	193 398	14.29	(13.76–14.83)	15 214	1 277 666	11.91	(11.72–12.10)	1.20	(1.15–1.25)
Males	2118	178 772	11.85	(11.35–12.36)	8350	854 940	9.77	(9.56–9.98)	1.21	(1.16–1.27)
Age group
18–49 years	771	70 273	10.97	(10.21–11.77)	7071	840 321	8.41	(8.22–8.61)	1.30	(1.21–1.40)
50–59 years	1602	126 856	12.63	(12.02–13.26)	7238	643 902	11.24	(10.98–11.50)	1.12	(1.06–1.19)
60–64 years	816	59 414	13.73	(12.81–14.71)	2957	227 335	13.01	(12.54–13.49)	1.06	(0.98–1.14)
≥65 years	1692	115 627	14.63	(13.94–15.35)	6298	421 048	14.96	(14.59–15.33)	0.98	(0.93–1.03)

	Diabetic Individuals				Nondiabetics Individuals				Difference
	Herpes Zoster Cases	Person- Years (PY)	Cases/ 1000 PY	95% Confidence Interval [CI]*	Herpes Zoster Cases	Person- Years (PY)	Cases/ 1000 PY	95% CI*	Incidence Rate Ratio	95% CI**
Total study population
Enrollees in group	61 142	7 681 336	7.96	(7.90–8.02)	359 373	80 266 547	4.48	(4.46–4.49)	1.78	(1.76–1.79)
Sex
Females	35 071	3 826 046	9.17	(9.07–9.26)	224 735	43 431 997	5.17	(5.15–5.20)	1.77	(1.75–1.79)
Males	26 071	3 855 290	6.76	(6.68–6.85)	134 638	36 834 550	3.66	(3.64–3.68)	1.85	(1.83–1.87)
Age group
18–49 years	12 441	2 464 386	5.05	(4.96–5.14)	169 277	51 819 510	3.27	(3.25–3.28)	1.55	(1.52–1.57)
50–59 years	22 284	2 821 550	7.90	(7.79–8.00)	104 908	17 041 888	6.16	(6.12–6.19)	1.28	(1.26–1.30)
60–64 years	9619	993 001	9.69	(9.49–9.88)	31 838	4 396 777	7.24	(7.16–7.32)	1.34	(1.31–1.37)
≥65 years	16 798	1 402 399	11.98	(11.80–12.16)	53 350	7 008 371	7.61	(7.55–7.68)	1.57	(1.55–1.60)
Immune competent
Enrollees in group	56 261	7 309 166	7.70	(7.63–7.76)	335 809	78 133 941	4.30	(4.28–4.31)	1.79	(1.78–1.81)
Sex
Females	32 308	3 632 648	8.89	(8.80–8.99)	209 521	42 154 331	4.97	(4.95–4.99)	1.79	(1.77–1.81)
Males	23 953	3 676 518	6.52	(6.43–6.60)	126 288	35 979 610	3.51	(3.49–3.53)	1.86	(1.83–1.88)
Age group
18–49 years	11 670	2 394 113	4.87	(4.79–4.96)	162 206	50 979 189	3.18	(3.17–3.20)	1.53	(1.50–1.56)
50–59 years	20 682	2 694 694	7.68	(7.57–7.78)	97 670	16 397 987	5.96	(5.92–5.99)	1.29	(1.27–1.31)
60–64 years	8803	933 587	9.43	(9.23–9.63)	28 881	4 169 442	6.93	(6.85–7.01)	1.36	(1.33–1.39)
≥65 years	15 106	1 286 772	11.74	(11.55–11.93)	47 052	6 587 323	7.14	(7.08–7.21)	1.64	(1.61–1.67)
Immune compromised
Enrollees in group	4881	372 169	13.12	(12.75–13.49)	23 564	2 132 606	11.05	(10.91–11.19)	1.19	(1.15–1.22)
Sex
Females	2763	193 398	14.29	(13.76–14.83)	15 214	1 277 666	11.91	(11.72–12.10)	1.20	(1.15–1.25)
Males	2118	178 772	11.85	(11.35–12.36)	8350	854 940	9.77	(9.56–9.98)	1.21	(1.16–1.27)
Age group
18–49 years	771	70 273	10.97	(10.21–11.77)	7071	840 321	8.41	(8.22–8.61)	1.30	(1.21–1.40)
50–59 years	1602	126 856	12.63	(12.02–13.26)	7238	643 902	11.24	(10.98–11.50)	1.12	(1.06–1.19)
60–64 years	816	59 414	13.73	(12.81–14.71)	2957	227 335	13.01	(12.54–13.49)	1.06	(0.98–1.14)
≥65 years	1692	115 627	14.63	(13.94–15.35)	6298	421 048	14.96	(14.59–15.33)	0.98	(0.93–1.03)

* 95% confidence interval (CI) was based on Poisson distribution.

** 95% CI of incidence rate ratio was based on Mantel–Haenszel combined estimate.

This Feature Is Available To Subscribers Only